Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Aesica and EmulTech Develop Sterile Emulsion Technology for Micro Encapsulation

Published: Monday, February 18, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
CMO’s Nottingham site first to use EmulTech’s ET4ME technology for GMP production of pharmaceuticals.

Aesica and EmulTech have jointly announced the commercial development of ET4ME - an innovative emulsion technology for product formulation.

ET4ME, a micro-encapsulation technology developed by the EmulTech group (a spin out of Eindhoven University of Technology), utilizes an elegant micro fluidic process to create a measurable micro particulate suspension where particle size is uniform and reproducible.

The technology can be used for a multitude of APIs from small molecules to complex biomolecules, with high levels of batch consistency and reproducibility upon scale up.

By utilizing a closed system, sterile formulations can be achieved, coupled with resistance to oxidative degradation.

The product is already being actively used by an Aesica client to help develop a new dosage form in an acid resistant non-sterile suspension.

However, the partners envisage huge growth in the use of this technology for sterile products following an externally validated process simulation trial (PST).

Over three years in development, and thanks to the creation of an aseptic protocol by Aesica, the technology has applications in the formulation of injectables - in particular depot injections for sustained release, due to the uniform droplet size, loading and morphology.

Formulations have demonstrated improved aqueous stability that will enable our customers to revisit previously abandoned products such as injectables, poor solubility compounds and new formulations of existing products.

Ian Lafferty, site director at Aesica formulation development, commented: We first came across the technology at a conference a few years ago and realized that if we could develop an aseptic process - it’s a tremendous credit to our development team that we could achieve this - it would provide an elegant solution to many compounds. Already, we have started working with several clients to commercialize this technology and there is a tremendous growth opportunity for sterile products and injectables.”

Fränk de Jong, CEO at EmulTech, added: “We knew we had a very innovative proprietary technology and by working with Aesica we now have access to their GMP approved facilities in Nottingham. This coupled with their ability to develop an aseptic process for the technology has enabled us to offer a commercialized solution that has the potential to develop formulations that would previously have been unachievable. Thanks to Aesica the process has been PST validated for steriles and there is a clear emerging demand to develop formulations using this approach.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Aesica Completes the Validation of its High Capacity Manufacturing Facility
$45m (USD) has been invested at its Queenborough, UK site.
Saturday, March 15, 2014
Aesica Appoints Ian Muir to Commercial Managing Director Position
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.
Tuesday, February 04, 2014
Aesica Awarded NEPIC Industry Award
Corporate HR Manager wins NEPIC 2014 Young Achiever Accolade within the Pharmaceutical category.
Thursday, January 30, 2014
Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
Tasked with optimizing performance schedules, including 4 new products for 2014.
Tuesday, November 26, 2013
Aesica Recruits New East Coast Business Development Manager
Appointment of Baali Muganga to spearhead growth in contract manufacturing market share across the US region.
Tuesday, October 29, 2013
Aesica Target Development Services at Growing Inhalation Market
CDMO’s Nottingham site a hot bed of innovation with unique spray drying, powder filling and dry powder inhaler technology.
Wednesday, October 16, 2013
Aesica Unveils a New High Capacity Manufacturing Facility
New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults.
Thursday, September 19, 2013
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos